- Home
- CTRM vs RLYB Comparison
CTRM vs RLYB Comparison
Compare CTRM & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- RLYB
- Stock Information
- Founded
- CTRM 2016
- RLYB 2018
- Country
- CTRM Cyprus
- RLYB United States
- Employees
- CTRM N/A
- RLYB N/A
- Industry
- CTRM Marine Transportation
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- RLYB Health Care
- Exchange
- CTRM Nasdaq
- RLYB Nasdaq
- Market Cap
- CTRM 25.0M
- RLYB 25.0M
- IPO Year
- CTRM N/A
- RLYB 2021
- Fundamental
- Price
- CTRM $2.12
- RLYB $0.30
- Analyst Decision
- CTRM
- RLYB Hold
- Analyst Count
- CTRM 0
- RLYB 5
- Target Price
- CTRM N/A
- RLYB $11.50
- AVG Volume (30 Days)
- CTRM 50.1K
- RLYB 201.6K
- Earning Date
- CTRM 05-15-2025
- RLYB 05-08-2025
- Dividend Yield
- CTRM N/A
- RLYB N/A
- EPS Growth
- CTRM N/A
- RLYB N/A
- EPS
- CTRM 2.39
- RLYB N/A
- Revenue
- CTRM $76,443,340.00
- RLYB $636,000.00
- Revenue This Year
- CTRM N/A
- RLYB N/A
- Revenue Next Year
- CTRM N/A
- RLYB N/A
- P/E Ratio
- CTRM $0.88
- RLYB N/A
- Revenue Growth
- CTRM N/A
- RLYB N/A
- 52 Week Low
- CTRM $1.98
- RLYB $0.22
- 52 Week High
- CTRM $5.49
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- CTRM 39.47
- RLYB 31.16
- Support Level
- CTRM $1.98
- RLYB $0.24
- Resistance Level
- CTRM $2.22
- RLYB $0.28
- Average True Range (ATR)
- CTRM 0.14
- RLYB 0.05
- MACD
- CTRM 0.01
- RLYB 0.00
- Stochastic Oscillator
- CTRM 45.16
- RLYB 18.31
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.